+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Head and Neck Cancer - Pipeline Insight, 2022

  • PDF Icon

    Drug Pipelines

  • 280 Pages
  • November 2022
  • Region: Global
  • DelveInsight
  • ID: 5695154
This “Head and Neck cancer - Pipeline Insight, 2022” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in Head and Neck cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Head and Neck cancer Understanding

Head and Neck cancer: Overview

Head and neck cancer is a collective term that includes several different types of cancers. Cancers of the head and neck are categorized by the area in which they begin. This includes the mouth (oral cavity), throat (pharynx), voice box (larynx), sinuses and nose cavity, and salivary glands. The most common type of head and neck cancer is squamous cell carcinoma of the head and neck (HNSCCA). Most HNSCCA begins in the layer of flat cells (the epithelium) which line the structures of the upper aerodigestive tract, including the mouth, throat, and voice box. HNSCCA accounts for about three to five percent of all cancers in the United States, where, in 2021, an estimated 54,000 people will be diagnosed with head and neck cancer and approximately 11,000 will die of the disease. Globally, there were an estimated 890,000 cases in 2018 along with 450,000 deaths. The five-year survival rate of patients with head and neck cancer is about 60 percent. Environmental risk factors for head and neck cancers include tobacco use, heavy alcohol consumption, prolonged sun exposure, and certain viruses, including human papilloma virus (HPV) and Epstein-Barr virus (EBV). Treatment for head and neck cancer depends on individual factors, including the exact location of the tumor, stage of the tumor, and a person's general health. These conventional treatments for head and neck cancer (surgery, radiation, and chemotherapy) may be used alone or in combination, depending on stage and location.

"Head and Neck cancer - Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Head and Neck cancer pipeline landscape is provided which includes the disease overview and Head and Neck cancer treatment guidelines. The assessment part of the report embraces, in depth Head and Neck cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Head and Neck cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Head and Neck cancer.
  • In the coming years, the Head and Neck cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Head and Neck cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Head and Neck cancer treatment market. Several potential therapies for Head and Neck cancer are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Head and Neck cancer market size in the coming years.
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Head and Neck cancer) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Head and Neck cancer Emerging Drugs Chapters

This segment of the Head and Neck cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Head and Neck cancer Emerging Drugs

Monalizumab: Innate Pharma

Monalizumab (IPH2201) is a potentially first-in-class immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor infiltrating cytotoxic CD8+ T cells and NK cells. NKG2A is an inhibitory checkpoint receptor for HLA-E. By expressing HLA-E, cancer cells can protect themselves from killing by NKG2A+ immune cells. HLA-E is frequently overexpressed on cancer cells of many solid tumors and hematological malignancies. Monalizumab may re-establish a broad anti-tumor response mediated by NK and T cells, and may enhance the cytotoxic potential of other therapeutic antibodies. Monalizumab is a blocking antibody that prevents the inhibition of CD8+ T cells and NK cell by tumor cells expressing HLA-E. By acting simultaneously on innate and adaptive immunity, monalizumab may re-establish a broad anti-tumor response. Currently, it is in Phase III stage of clinical trial evaluation to treat Squamous Cell Carcinoma of the Head and Neck.

Niraparib: GlaxoSmithKline

Niraparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP-1 and PARP-2, which play a role in DNA repair. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis and cell death. Increased niraparib-induced cytotoxicity was observed in tumor cell lines with or without deficiencies in BRCA1/2. Niraparib decreased tumor growth in mouse xenograft models of human cancer cell lines with deficiencies in BRCA1/2 and in human patient-derived xenograft tumor models with homologous recombination deficiency that had either mutated or wild type BRCA1/2.

Xevinapant: Debiopharm

Xevinapant (Debio 1143) is a potential first-in-class potent oral antagonist of IAPs (Inhibitor of Apoptosis Proteins). In preclinical studies, xevinapant restores sensitivity to apoptosis in cancer cells, thereby depriving them of one of their major resistance mechanisms. As the most clinically advanced IAP antagonist, xevinapant has established proof of efficacy in combination with chemoradiotherapy (CRT) in patients with high-risk locally advanced squamous cell carcinoma of the head and neck (LA SCCHN), with a clinically significant and sustained clinical benefit compared with CRT alone.

Enoblituzumab: MacroGenics

Enoblituzumab is an investigational monoclonal antibody that targets B7-H3 and has been enhanced using MacroGenics' Fc Optimization platform. B7-H3 is a protein in the B7 family of immune regulator proteins. B7-H3 is widely expressed by a number of different tumor types and may play a key role in regulating the immune response to various types of cancer. MacroGenics is collaborating on the development and commercialization of enoblituzumab with I-Mab Biopharma in Greater China. MacroGenics retains full development and commercialization rights in all other territories. Currently, it is in Phase II stage of clinical trial evaluation to treat Head and Neck cancer.

Head and Neck cancer: Therapeutic Assessment

This segment of the report provides insights about the different Head and Neck cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Head and Neck cancer

There are approx. 150+ key companies which are developing the therapies for Head and Neck cancer. The companies which have their Head and Neck cancer drug candidates in the most advanced stage, i.e. phase III include, Innate Pharma.

Phases

The report covers around 150+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Head and Neck cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Inhalation
  • Inhalation/Intravenous/Oral
  • Intranasal
  • Intravenous
  • Intravenous/ Subcutaneous
  • NA
  • Oral
  • Oral/intranasal/subcutaneous
  • Parenteral
  • Subcutaneous
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Antibody
  • Antisense oligonucleotides
  • Immunotherapy
  • Monoclonal antibody
  • Peptides
  • Protein
  • Recombinant protein
  • Small molecule
  • Stem Cell
  • Vaccine
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Head and Neck cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Head and Neck cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Head and Neck cancer drugs.

Head and Neck cancer Report Insights

  • Head and Neck cancer Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Head and Neck cancer Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Head and Neck cancer drugs?
  • How many Head and Neck cancer drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Head and Neck cancer?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Head and Neck cancer therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Head and Neck cancer and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Innate Pharma
  • GlaxoSmithKline
  • Debiopharm
  • MacroGenics
  • Takeda Oncology
  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
  • PNP Therapeutics, Inc.
  • IntraGel Therapeutics
  • Incyte Corporation
  • Corregene Biotechnology Co., Ltd
  • TyrNovo Ltd.
  • BioNTech SE
  • Adlai Nortye Biopharma Co., Ltd.
  • Merck KGaA
  • Aveta Biomics, Inc.
  • Cellectar Biosciences, Inc.
  • Nanobiotix
  • ALX Oncology
  • Nektar Therapeutics
  • Ikena Oncology
  • AstraZeneca
  • Arcus Biosciences, Inc.
  • Roche
  • Vaccinex
  • Pfizer
  • Astex Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Bayer HealthCare
  • Kura Oncology
  • Cue Biopharma
  • Shanghai Henlius Biotech
  • Merus N.V.
  • NanoCarrier Co., Ltd.
  • Alkermes, Inc.
  • Rubius Therapeutics
  • iTeos Belgium SA
  • Transgene
  • Boehringer Ingelheim
  • Immutep S.A.S.
  • Compugen Ltd
  • Galectin Therapeutics
  • BioAtla, Inc.
  • Betta Pharmaceuticals Co., Ltd.
  • Jacobio Pharmaceuticals Co., Ltd.
  • CytomX Therapeutics
  • Advaxis, Inc.
  • Inhibrx, Inc.
  • Celldex Therapeutics
  • Carisma Therapeutics Inc
  • Intensity Therapeutics, Inc.
  • I-Mab Biopharma
  • Quadriga Biosciences, Inc.
  • Checkpoint Therapeutics, Inc.
  • Wellmarker Bio
  • Genentech, Inc.
  • Pionyr Immunotherapeutics Inc.
  • Cyteir Therapeutics, Inc.
  • Klus Pharma Inc.
  • Bicycle Therapeutics
  • Palleon Pharmaceuticals, Inc.
  • Rapa Therapeutics
  • SN BioScience
  • Memgen, Inc.

Key Products

  • Monalizumab
  • Niraparib
  • Xevinapant
  • Enoblituzumab
  • CK-301
  • QBS10072S
  • A166
  • E-602
  • BT5528
  • TAK-981
  • RAPA-201
  • Mitoxantrone Hydrochloride
  • MEM-288
  • TJ004309
  • SNB-101
  • INT230-6
  • CT-0508
  • WM-S1-030
  • CDX-1140
  • PY159
  • MCLA-129
  • INBRX-106
  • Autogene cevumeran
  • JAB-3068
  • CAB-ROR2-ADC
  • ADXS-NEO
  • CX-2029
  • Ad/PNP
  • COM701
  • Eftilagimod alpha
  • CYT-0851
  • GR-MD-02
  • TG4050
  • BI 765063
  • TumoCure
  • EOS-448
  • Epacadostat
  • RTX-321
  • CUE-101
  • ALKS 4230
  • CRTE7A2-01
  • NC-6004
  • Tipifarnib
  • MCLA-129
  • Zimberelimab
  • HLX10 Plus HLX07
  • Tolinapant
  • BAY1905254
  • OSI-774
  • cetuximab
  • VX15/2503
  • Palbociclib
  • Olaparib
  • NT219
  • BNT113
  • Buparlisib
  • Retifanlimab
  • Avelumab
  • APG-157
  • CLR 131
  • NBTXR3
  • Evorpacept
  • Dostarlimab
  • NKTR-214
  • IK-175


This product will be delivered within 1-3 business days.

Table of Contents

IntroductionExecutive Summary
Head and Neck cancer: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Head and Neck cancer - Analytical Perspective
Late Stage Products (Phase III)
  • Comparative Analysis
Monalizumab: Innate Pharma
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Enoblituzumab: MacroGenics
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
IK-175: Ikena Oncology
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical and Discovery Stage Products
  • Comparative Analysis
Research programme: cancer vaccines - Voltron Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Head and Neck cancer Key CompaniesHead and Neck cancer Key ProductsHead and Neck cancer- Unmet NeedsHead and Neck cancer- Market Drivers and BarriersHead and Neck cancer- Future Perspectives and ConclusionHead and Neck cancer Analyst ViewsHead and Neck cancer Key CompaniesAppendix
List of Tables
Table 1 Total Products for Head and Neck cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
List of Figures
Figure 1 Total Products for Head and Neck cancer
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Innate Pharma
  • GlaxoSmithKline
  • Debiopharm
  • MacroGenics
  • Takeda Oncology
  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
  • PNP Therapeutics, Inc.
  • IntraGel Therapeutics
  • Incyte Corporation
  • Corregene Biotechnology Co., Ltd
  • TyrNovo Ltd.
  • BioNTech SE
  • Adlai Nortye Biopharma Co., Ltd.
  • Merck KGaA
  • Aveta Biomics, Inc.
  • Cellectar Biosciences, Inc.
  • Nanobiotix
  • ALX Oncology
  • Nektar Therapeutics
  • Ikena Oncology
  • AstraZeneca
  • Arcus Biosciences, Inc.
  • Roche
  • Vaccinex
  • Pfizer
  • Astex Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Bayer HealthCare
  • Kura Oncology
  • Cue Biopharma
  • Shanghai Henlius Biotech
  • Merus N.V.
  • NanoCarrier Co., Ltd.
  • Alkermes, Inc.
  • Rubius Therapeutics
  • iTeos Belgium SA
  • Transgene
  • Boehringer Ingelheim
  • Immutep S.A.S.
  • Compugen Ltd
  • Galectin Therapeutics
  • BioAtla, Inc.
  • Betta Pharmaceuticals Co., Ltd.
  • Jacobio Pharmaceuticals Co., Ltd.
  • CytomX Therapeutics
  • Advaxis, Inc.
  • Inhibrx, Inc.
  • Celldex Therapeutics
  • Carisma Therapeutics Inc
  • Intensity Therapeutics, Inc.
  • I-Mab Biopharma
  • Quadriga Biosciences, Inc.
  • Checkpoint Therapeutics, Inc.
  • Wellmarker Bio
  • Genentech, Inc.
  • Pionyr Immunotherapeutics Inc.
  • Cyteir Therapeutics, Inc.
  • Klus Pharma Inc.
  • Bicycle Therapeutics
  • Palleon Pharmaceuticals, Inc.
  • Rapa Therapeutics
  • SN BioScience
  • Memgen, Inc.